Executive Insights: Competition with China - India Life Sciences 2023

Executive Insights: Competition with China

Hear how industry executives view their country’s relationship with the Chinese pharmaceutical industry

“Through government incentives like the PLI scheme, significant investments have led to the creation of new innovation hubs where companies are incentivized to invest in the API space. We have yet to fully realize the benefit of this, as it does not happen overnight.”

Riddhi Javeri, Director, InterMed Laboratories

“We are already exporting APIs directly to China, and with India becoming increasingly competitive, we believe China will soon be dependent on India for various raw materials instead of the other way around.”

Atman Parekh, Executive Director, Atman Pharmaceuticals

“China has historically been the dominant player in animal health, but India is emerging as a strong substitute.”

Rahul Nachane, Managing Director, NGL Fine-Chem

“The truth is that India will always have to do business with China. We can reduce our dependencies, and we do see price advantages for certain basic chemicals being manufactured in India, but I do not see a dramatic shift in dependency within the next 10-15 years.”

Ravi Jagtap, Founder & Managing Director, Aastrid Life Sciences

“One thing that differentiates India’s pharma sector from China’s is the emphasis we place on long-term relationships with our customers. These relationships are based on quality and on time delivery.”

Ramesh Chodvadiya, Managing Director, Prudence Pharma Chem

Image courtesy of Deposit photos

Next:

Interview: Merck Life Science